Rigatelli Gianluca, Rossini Katia, Vindigni Vincenzo, Mazzoleni Francesco, Rigatelli Giorgio, Carraro Ugo
EndoCardioVascular Therapy Research, Legnago, Verona, Italy.
Cardiovasc Radiat Med. 2004 Apr-Jun;5(2):84-7. doi: 10.1016/j.carrad.2004.05.003.
Autologous skeletal myoblast transplantation may be used to ameliorate the healing process following myocardium infarct and, hopefully, cardiomyopathies. Despite successful animal experimentation, several issues need to be addressed in clinical settings, i.e., the impact of the delivery route, the extent of short- and long-term survival, and differentiation of the injected skeletal myoblasts. The authors offer some new hypotheses resulting from basic research, i.e., where and when to inject the myogenic cells, whatever their source, how to decrease new myofiber atrophy and improve their regeneration. Although these new hypotheses still need to be tested in humans, they may be decisive for future experimental studies and will lead to making endovascular cell implantation a more effective way to treat ischemic heart disease and failure.
自体骨骼肌成肌细胞移植可用于改善心肌梗死后以及有望改善心肌病后的愈合过程。尽管动物实验取得了成功，但在临床环境中仍有几个问题需要解决，即给药途径的影响、注射的骨骼肌成肌细胞的短期和长期存活程度以及分化情况。作者提出了一些基础研究得出的新假设，即无论肌源性细胞来源如何，在何处以及何时注射这些细胞，如何减少新肌纤维萎缩并改善其再生。尽管这些新假设仍需在人体中进行测试，但它们可能对未来的实验研究具有决定性意义，并将使血管内细胞植入成为治疗缺血性心脏病和心力衰竭的更有效方法。
